CN Patent
CN112439069A — 一种vegfr抑制剂在制备治疗移植物抗宿主病的药物中的用途
Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2021-03-05 · 5y expired
What this patent protects
本公开中涉及一种VEGFR抑制剂在制备治疗移植物抗宿主病的药物中的用途。具体而言,所述移植物抗宿主病(GVHD)包括急性性抗宿主病(aGVHD)和慢性抗宿主病(cGVHD),所述VEGFR抑制剂选自阿帕替尼或其可药用盐。
USPTO Abstract
本公开中涉及一种VEGFR抑制剂在制备治疗移植物抗宿主病的药物中的用途。具体而言,所述移植物抗宿主病(GVHD)包括急性性抗宿主病(aGVHD)和慢性抗宿主病(cGVHD),所述VEGFR抑制剂选自阿帕替尼或其可药用盐。
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.